Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160
Annals of Rheumatic Diseases,

Smolen JS et al. – In patients with active rheumatoid arthritis (RA) who discontinued previous TNF–antagonist treatment, golimumab 50 and 100 mg injections every 4 weeks yielded sustained improvements in signs/symptoms and physical function in 57–67% of patients who continued treatment. Golimumab safety was consistent with other anti–TNF agents, although definitive conclusions regarding long–term safety require further monitoring.

Methods
  • Results through week 24 of this multicentre, randomised, double–blind, placebo–controlled study of active RA (≥ 4 tender, ≥ 4 swollen joints) were previously reported.
  • Patients received placebo (Group 1), 50 mg golimumab (Group 2) or 100 mg golimumab (Group 3) subcutaneous injections every 4 weeks.
  • Patients from Groups 1 and 2 with <20% improvement in tender/swollen joints at week 16 early escaped to golimumab 50 mg and 100 mg, respectively.
  • At week 24, Group 1 patients crossed over to golimumab 50 mg, Group 2 continued golimumab 50/100 mg per escape status and Group 3 maintained dosing..
  • Data through week 160 are reported

Results
  • 459 of the 461 randomised patients were treated; 236/459 (51%) continued treatment through week 160.
  • From week 24 to week 100, ACR20 (≥ 20% improvement in American College of Rheumatology criteria) response and ≥ 0.25 unit HAQ (Health Assessment Questionnaire) improvement were sustained in 70–73% and 75–81% of responding patients, respectively.
  • Overall at week 160, 63%, 67% and 57% of patients achieved ACR20 response and 59%, 65% and 64% had HAQ improvement ≥ 0.25 unit in Groups 1, 2 and 3, respectively.
  • Adjusted for follow–up duration, adverse event incidences (95% CI) per 100 patient–years among patients treated with golimumab 50 mg and 100 mg were 4.70 (2.63 to 7.75) and 8.07 (6.02 to 10.58) for serious infection, 0.95 (0.20 to 2.77) and 2.04 (1.09 to 3.49) for malignancy and 0.00 (0.00 to 0.94) and 0.62 (0.17 to 1.59) for death, respectively.

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access PubMed, Publisher and related articles...

Your Unread Messages in Rheumatology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Rheumatology Articles

1 Non-steroidal anti-inflammatory drugs and risk of cardiovascular disease in patients with rheumatoid arthritis: A nationwide cohort study Annals of Rheumatic Diseases, July 14, 2014    Clinical Article

2 Is minor salivary gland biopsy more than a diagnostic tool in primary Sjogren's syndrome? Association between clinical, histopathological, and molecular features: A retrospective study Seminars in Arthritis and Rheumatism, July 1, 2014    Clinical Article

3 Risk of herpes/herpes zoster during anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Systematic review and meta-analysis Joint, Bone, Spine, July 3, 2014    Clinical Article

4 Methotrexate and lung disease in rheumatoid arthritis – A meta-analysis of randomized controlled trials Arthritis & Rheumatism, December 27, 2013    Evidence Based Medicine    Review Article    Clinical Article

5 Anti-TNF-{alpha} therapy in patients with refractory uveitis due to Behcet's disease: A 1-year follow-up study of 124 patients Rheumatology, July 8, 2014    Clinical Article

6 Anti-cyclic citrullinated peptide antibody as a marker of erosive arthritis in patients with systemic lupus erythematosus: A systematic review and meta-analysis Lupus, July 11, 2014    Clinical Article

7 Sugar-sweetened soda consumption and risk of developing rheumatoid arthritis in women American Journal of Clinical Nutrition, July 18, 2014    Review Article

8 Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: Drug-exposure limitations of oral methotrexate at doses >=15 mg may be overcome with subcutaneous administration Annals of Rheumatic Diseases, July 10, 2014    Clinical Article

9 An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegeners) Annals of Rheumatic Diseases, July 2, 2014

10 Therapeutic benefit of balneotherapy and hydrotherapy in the management of fibromyalgia syndrome: A qualitative systematic review and meta-analysis of randomized controlled trials Arthritis Research & Therapy, July 9, 2014    Evidence Based Medicine    Review Article

11 Ultrasound-detected musculoskeletal urate crystal deposition: Which joints and what findings should be assessed for diagnosing gout? Annals of Rheumatic Diseases, July 14, 2014    Clinical Article

12 Treatment with angiotensin II receptor blockers is associated with prolonged relapse-free survival, lower relapse rate, and corticosteroid-sparing effect in patients with giant cell arteritis Seminars in Arthritis and Rheumatism, July 8, 2014    Clinical Article

13 Diagnostic accuracies of sialography and salivary ultrasonography in Sjögren`s syndrome patients: A meta-analysis Clinical and Experimental Rheumatology Online, July 16, 2014    Clinical Article

14 Subcutaneous administration of methotrexate with a prefilled autoinjector pen results in a higher relative bioavailability compared with oral administration of methotrexate Clinical and Experimental Rheumatology Online, July 7, 2014    Clinical Article

15 Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs - a systematic review and network meta-analysis Full Text Health and Quality of Life Outcomes , July 22, 2014    Free full text    Evidence Based Medicine    Review Article

16 Risk of malignancy in patients with giant cell arteritis and polymyalgia rheumatica: A systematic review and meta-analysis Seminars in Arthritis and Rheumatism, June 27, 2014    Evidence Based Medicine    Review Article

17 Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: A clinical observational study Rheumatology, February 11, 2014    Clinical Article

18 Joint damage progression in patients with rheumatoid arthritis in clinical remission. do biologics perform better than synthetic antirheumatic drugs? The Journal of Rheumatology, July 22, 2014    Clinical Article

19 Evaluation of low-dose rituximab for the retreatment of patients with active rheumatoid arthritis: A non-inferiority randomised controlled trial Annals of Rheumatic Diseases, July 16, 2014    Clinical Article

20 Relation of temperature and humidity to the risk of recurrent gout attacks American Journal of Epidemiology, July 11, 2014    Clinical Article

Indexed Journals in Rheumatology: Arthritis & Rheumatism, Annals of Rheumatic Diseases, Journal of Rheumatologymore

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Connect with us, stay current.

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Close